Eli Lilly and Company completed its acquisition of Adverum Biotechnologies, Inc. on 2025-11-07, according to the Form 8-K Adverum Biotechnologies, Inc. filed with the SEC on 2025-12-09. The filing's Item 2.01 states no aggregate dollar price. Adverum Biotechnologies, Inc. filed the report because the deal made it part of Eli Lilly and Company.
| Acquirer | Eli Lilly and Company |
|---|---|
| Acquired | Adverum Biotechnologies, Inc. |
| Completed | 2025-11-07 |
| Reported by | Adverum Biotechnologies, Inc. (ADVM), the company acquired |
| Filing | Form 8-K, filed 2025-12-09 |
Want the whole picture on Eli Lilly and Company?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Eli Lilly and Company: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Eli Lilly and Company covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
Upon the consummation of the Merger, the Company became a direct wholly owned subsidiary of Parent. 2
More from the filing
As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on October 24, 2025, Adverum Biotechnologies, Inc., a Delaware corporation ("Adverum" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 24, 2025, by and among the Company, Eli Lilly and Company, an Indiana corporation ("Parent"), and Flying Tigers Acquisition Corporation, a Delaware corporation and direct wholly owned subsidiary of Parent ("Purchaser").
Pursuant to the Merger Agreement, on November 7, 2025, Purchaser commenced a tender offer (the "Offer") to purchase all of the issued and outstanding shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Company Common Stock") in exchange for (i) $3.56 per Share, net to the stockholder in cash, without interest (the "Closing Amount") and less any applicable tax withholding, plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive up to two contingent cash payments of up to an aggregate of $8.91 per CVR
The Offer and related withdrawal rights expired, as scheduled, one minute past 11:59 p.m., Eastern Time, on December 8, 2025 (such date and time, the "Expiration Time").
Quoted from Adverum Biotechnologies, Inc.'s Form 8-K.
Other acquisitions by Eli Lilly and Company
| Completed | Acquired | Price stated |
|---|---|---|
| 2026-03-04 | Ventyx Biosciences, Inc. | $1.2 billion |
| 2026-09-11 | AtaiBeckley Inc. | Not stated |
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Eli Lilly and CompanyLook up Eli Lilly and Company and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.